Imatinib Mesylate

규격

220127-57-1CAS 번호

606-892-3EC 번호

methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamideIUPAC 명칭

C30H35N7O4S화학식

589.7 g/mol분자량

Imatinib mesylate; 220127-57-1; Gleevec; Glivec; Imatinib mesilate; imatinib methanesulfonate; sti-571; Imatinib accord; Imatinib medac; STI 571; Imatinib (as mesilate); NSC-716051; DTXSID9040502; QTI-571; Imatinib methane sulfonate; IMKELDI; QTI571; 8A1O1M485B; DTXCID7020502; CHEBI:31690; CGP-57148; NSC716051; imatinib oral; Mesylate, Imatinib; RefChem:77; alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Methanesulfonate, Imatinib; Imatinib mesylate 400 mg; CGP57148B; CGP57148; 4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide Monomethanesulfonate; CGP 57148; STI571; Imatinib Mesylate (STI571); Gleevec (Imatinib mesylate); MFCD04307699; Imatinib (mesylate); imatinib monomesylate; CGP-57148B; Imatinib mesylate [USAN]; N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate; CGP 57148B; Imatinib mesilate (JAN); Imatinib mesylate (USAN); M06311; Imatinib Mesylate(|A form); Imatinib Methansulfonate; IMATINIB MESILATE [JAN]; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1); CAS-220127-57-1; 220127-57-1 (mesylate); NCGC00159456-02; Genfatinib; Gleevac; Shantinib; Imatinib, methanesulfonate salt; Gleevec;; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate; C30H35N7O4S; HSDB 7142; Imatinib mesylate?; 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide methanesulfonate; Gleevec (TN); Glivec (TN); Imatinib mesilate CRS; Imatinib(free base)?; ST-1571 Mesylate; Imatinib Mesylate Tablets; SCHEMBL8217; Imatinib monomethanesulfonate; CHEMBL1642; Benzamide,monomethanesulfonate; MLS001401456; UNII-8A1O1M485B; orb1307991; Imatinib (Mesylate) (Standard); IMATINIB MESYLATE [HSDB]; SCHEMBL15632914; SCHEMBL29370699; SCHEMBL29377238; EX-A954; IMATINIB MESYLATE [VANDF]; IMATINIB MESILATE [MART.]; YLMAHDNUQAMNNX-UHFFFAOYSA-N; GGP-57148B; GLXC-05064; HMS2052B09; HMS2233D16; HMS3265E01; HMS3265E02; HMS3265F01; HMS3265F02; HMS3372O12; HMS3394B09; HMS3654C07; HMS5079E05; IMATINIB MESILATE [WHO-DD]; Imatinib for system suitability CRS; Tox21_111684; AC-525; HB1943; HY-50946R; s1026; Imatinib mesylate - Bio-X trade mark; IMATINIB METHANESULFONATE [MI]; AKOS015852497; Tox21_111684_1; CCG-101175; FI10812; IMATINIB MESYLATE [ORANGE BOOK]; KS-1236; NC00425; NSC 716051; IMATINIB MESILATE [EP MONOGRAPH]; NCGC00159456-11; 111GE005; 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate; Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-, monomethanesulfonate; BI164678; HY-50946; methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate; SMR000469175; SY013513; I0936; I4802; NS00076459; SW197805-4; D01441; Imatinib Mesylate (CGP-57148B, STI-571); Q27114666; Imatinib Mesylate,Gleevec,Glivec,CGP-57148B,STI-571; 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamidemethanesulfonic acid salt; 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide methanesulfonic acid salt; 4-[(4-Methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide monomethanesulphonate; 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate; 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide mesylate; 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate; hydron;methanesulfonate;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; Methanesulfonic acid--4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide (1/1); methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]phenyl]benzamide; N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamidemethanesulfonate동의어